En­ta­sis lands first an­tibi­ot­ic ap­proval eight years af­ter spin­ning out of As­traZeneca

Al­most eight years af­ter spin­ning out As­traZeneca’s an­tibi­otics pipeline, En­ta­sis Ther­a­peu­tics has land­ed its first ap­proval.

The FDA ap­proved its Xac­duro, made up of sul­bac­tam and dur­lobac­tam in­jec­tions, as a treat­ment for pneu­mo­nia caused by dif­fi­cult-to-treat bac­te­ria strains known as Acine­to­bac­ter bau­man­nii-cal­coaceti­cus com­plex (A. bau­man­nii) among adult pa­tients. Par­tic­u­lar­ly among al­ready vul­ner­a­ble hos­pi­tal­ized pa­tients, these in­fec­tions can be dead­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER